Lenalidomide targets Rho GTPase signaling in T cells from CLL patients. IRM quantification of the (Ai) area (μm2) and (Aii) strength (pixel intensity) of close cell contact points during LFA-1–directed motility on CD54 (following chemokine CXCL12 stimulation) for n = 30 T cells (individual dots) per experimental population is depicted, as indicated. T cells from CLL patients were compared with age-matched healthy donors treated with or without a pharmacologic inhibitor targeting (A) Rac1 or (B) the RhoA subfamily, or (C) transfected with GFP vector alone or with constitutive active Cdc42 (GFP-tagged V12 construct) with cells selected for analysis on the basis of GFP expression. Patient cells were analyzed with or without cotreatment of lenalidomide (Lenalid.). Dot plots are representative of 3 independent CLL patient experiments. **P < .01. black horizontal bar, mean values; ns, nonsignificant findings.
